6.855 USD
0 (-0.07%)
MDXG gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. While MDXG has a great health rating, its profitability is only average at the moment. MDXG is valued quite cheap, while showing a decent growth score. This is a good combination! These ratings could make MDXG a good candidate for value investing.
1. Profitability
1.1 Basic Checks
In the past year MDXG was profitable.
In the past year MDXG had a positive cash flow from operations.
In multiple years MDXG reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: MDXG reported negative operating cash flow in multiple years.
1.2 Ratios
The Return On Assets of MDXG (12.80%) is better than 94.57% of its industry peers.
With an excellent Return On Equity value of 17.09%, MDXG belongs to the best of the industry, outperforming 95.13% of the companies in the same industry.
MDXG has a better Return On Invested Capital (15.15%) than 95.69% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.8% | ||
| ROE | 17.09% | ||
| ROIC | 15.15% |
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of MDXG (10.38%) is better than 92.13% of its industry peers.
With an excellent Operating Margin value of 13.73%, MDXG belongs to the best of the industry, outperforming 93.07% of the companies in the same industry.
MDXG's Operating Margin has been stable in the last couple of years.
MDXG's Gross Margin of 81.99% is amongst the best of the industry. MDXG outperforms 85.39% of its industry peers.
MDXG's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.73% | ||
| PM (TTM) | 10.38% | ||
| GM | 81.99% |
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so MDXG is still creating some value.
Compared to 1 year ago, MDXG has more shares outstanding
MDXG has more shares outstanding than it did 5 years ago.
The debt/assets ratio for MDXG has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 9.89 indicates that MDXG is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 9.89, MDXG belongs to the top of the industry, outperforming 81.84% of the companies in the same industry.
The Debt to FCF ratio of MDXG is 0.27, which is an excellent value as it means it would take MDXG, only 0.27 years of fcf income to pay off all of its debts.
MDXG has a better Debt to FCF ratio (0.27) than 95.13% of its industry peers.
A Debt/Equity ratio of 0.07 indicates that MDXG is not too dependend on debt financing.
The Debt to Equity ratio of MDXG (0.07) is worse than 61.61% of its industry peers.
Although MDXG does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.27 | ||
| Altman-Z | 9.89 |
ROIC/WACC1.76
WACC8.61%
2.3 Liquidity
A Current Ratio of 4.41 indicates that MDXG has no problem at all paying its short term obligations.
MDXG has a Current ratio of 4.41. This is comparable to the rest of the industry: MDXG outperforms 50.75% of its industry peers.
MDXG has a Quick Ratio of 3.95. This indicates that MDXG is financially healthy and has no problem in meeting its short term obligations.
MDXG has a Quick ratio (3.95) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.41 | ||
| Quick Ratio | 3.95 |
3. Growth
3.1 Past
MDXG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -35.71%.
Looking at the last year, MDXG shows a quite strong growth in Revenue. The Revenue has grown by 14.77% in the last year.
MDXG shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.11% yearly.
EPS 1Y (TTM)-35.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
Revenue 1Y (TTM)14.77%
Revenue growth 3Y10.5%
Revenue growth 5Y3.11%
Sales Q2Q%35.3%
3.2 Future
MDXG is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.40% yearly.
Based on estimates for the next years, MDXG will show a quite strong growth in Revenue. The Revenue will grow by 14.49% on average per year.
EPS Next Y49.48%
EPS Next 2Y8.55%
EPS Next 3Y17.4%
EPS Next 5YN/A
Revenue Next Year17.88%
Revenue Next 2Y9.84%
Revenue Next 3Y10.43%
Revenue Next 5Y14.49%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 19.04, MDXG is valued on the expensive side.
Compared to the rest of the industry, the Price/Earnings ratio of MDXG indicates a rather cheap valuation: MDXG is cheaper than 94.19% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.41, MDXG is valued a bit cheaper.
With a Price/Forward Earnings ratio of 20.06, MDXG is valued on the expensive side.
Based on the Price/Forward Earnings ratio, MDXG is valued cheaper than 94.19% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 35.40, MDXG is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.04 | ||
| Fwd PE | 20.06 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, MDXG is valued cheaply inside the industry as 95.51% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, MDXG is valued cheaper than 96.25% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 15.2 | ||
| EV/EBITDA | 12.99 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of MDXG may justify a higher PE ratio.
MDXG's earnings are expected to grow with 17.40% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.38
PEG (5Y)N/A
EPS Next 2Y8.55%
EPS Next 3Y17.4%
5. Dividend
5.1 Amount
MDXG does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:MDXG (12/5/2025, 1:29:38 PM)
6.855
0 (-0.07%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners71.57%
Inst Owner Change-0.71%
Ins Owners1.83%
Ins Owner Change0.17%
Market Cap1.02B
Revenue(TTM)393.44M
Net Income(TTM)40.83M
Analysts81.82
Price Target12.44 (81.47%)
Short Float %3.22%
Short Ratio5.42
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)95.82%
Min EPS beat(2)81.55%
Max EPS beat(2)110.08%
EPS beat(4)3
Avg EPS beat(4)41.67%
Min EPS beat(4)-31.92%
Max EPS beat(4)110.08%
EPS beat(8)7
Avg EPS beat(8)78.91%
EPS beat(12)11
Avg EPS beat(12)70.05%
EPS beat(16)12
Avg EPS beat(16)53.63%
Revenue beat(2)2
Avg Revenue beat(2)12.56%
Min Revenue beat(2)6.68%
Max Revenue beat(2)18.43%
Revenue beat(4)4
Avg Revenue beat(4)6.82%
Min Revenue beat(4)0.32%
Max Revenue beat(4)18.43%
Revenue beat(8)6
Avg Revenue beat(8)3.48%
Revenue beat(12)9
Avg Revenue beat(12)3.71%
Revenue beat(16)12
Avg Revenue beat(16)3.45%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)21.15%
EPS NQ rev (3m)21.15%
EPS NY rev (1m)30.77%
EPS NY rev (3m)30.77%
Revenue NQ rev (1m)2.37%
Revenue NQ rev (3m)2.37%
Revenue NY rev (1m)5.61%
Revenue NY rev (3m)5.61%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.04 | ||
| Fwd PE | 20.06 | ||
| P/S | 2.58 | ||
| P/FCF | 15.2 | ||
| P/OCF | 14.97 | ||
| P/B | 4.25 | ||
| P/tB | 4.87 | ||
| EV/EBITDA | 12.99 |
EPS(TTM)0.36
EY5.25%
EPS(NY)0.34
Fwd EY4.98%
FCF(TTM)0.45
FCFY6.58%
OCF(TTM)0.46
OCFY6.68%
SpS2.66
BVpS1.61
TBVpS1.41
PEG (NY)0.38
PEG (5Y)N/A
Graham Number3.62
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.8% | ||
| ROE | 17.09% | ||
| ROCE | 20.67% | ||
| ROIC | 15.15% | ||
| ROICexc | 33.2% | ||
| ROICexgc | 44.66% | ||
| OM | 13.73% | ||
| PM (TTM) | 10.38% | ||
| GM | 81.99% | ||
| FCFM | 16.98% |
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-47.46%
ROICexc growth 3YN/A
ROICexc growth 5Y-21.46%
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
F-Score6
Asset Turnover1.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.27 | ||
| Debt/EBITDA | 0.25 | ||
| Cap/Depr | 6.96% | ||
| Cap/Sales | 0.26% | ||
| Interest Coverage | 36.69 | ||
| Cash Conversion | 98.8% | ||
| Profit Quality | 163.64% | ||
| Current Ratio | 4.41 | ||
| Quick Ratio | 3.95 | ||
| Altman-Z | 9.89 |
F-Score6
WACC8.61%
ROIC/WACC1.76
Cap/Depr(3y)52.31%
Cap/Depr(5y)58.09%
Cap/Sales(3y)0.72%
Cap/Sales(5y)1.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-35.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
EPS Next Y49.48%
EPS Next 2Y8.55%
EPS Next 3Y17.4%
EPS Next 5YN/A
Revenue 1Y (TTM)14.77%
Revenue growth 3Y10.5%
Revenue growth 5Y3.11%
Sales Q2Q%35.3%
Revenue Next Year17.88%
Revenue Next 2Y9.84%
Revenue Next 3Y10.43%
Revenue Next 5Y14.49%
EBIT growth 1Y-14.78%
EBIT growth 3YN/A
EBIT growth 5Y2.02%
EBIT Next Year35.54%
EBIT Next 3Y15.54%
EBIT Next 5Y22.59%
FCF growth 1Y787.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y522.28%
OCF growth 3YN/A
OCF growth 5YN/A
MIMEDX GROUP INC / MDXG FAQ
Can you provide the ChartMill fundamental rating for MIMEDX GROUP INC?
ChartMill assigns a fundamental rating of 6 / 10 to MDXG.
What is the valuation status of MIMEDX GROUP INC (MDXG) stock?
ChartMill assigns a valuation rating of 7 / 10 to MIMEDX GROUP INC (MDXG). This can be considered as Undervalued.
What is the profitability of MDXG stock?
MIMEDX GROUP INC (MDXG) has a profitability rating of 6 / 10.
What is the valuation of MIMEDX GROUP INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for MIMEDX GROUP INC (MDXG) is 19.04 and the Price/Book (PB) ratio is 4.25.
What is the financial health of MIMEDX GROUP INC (MDXG) stock?
The financial health rating of MIMEDX GROUP INC (MDXG) is 7 / 10.